MASTER SERVICES AGREEMENTMaster Services Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances) • Virginia
This Master Services Agreement (the “Agreement”) is made and entered into on 26 September 2012, (the “Effective Date”), by and between CEL-SCI Corporation, with offices at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182, USA (hereinafter referred to as “Client”) and Aptiv Solutions, Inc., together with its Affiliates, with offices at 1925 Isaac Newton Square, Suite 100, Reston, Virginia 20190 (hereinafter referred to as “Aptiv Solutions”), both hereinafter referred as a “Party” or collectively as the "Parties".
DATED: OCTOBER 10, 2013 CO-DEVELOPMENT AND REVENUE SHARING AGREEMENT II: Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women (“CIN”) BETWEEN CEL-SCI Corporation AND Ergomed Clinical Research LimitedCo-Development and Revenue Sharing Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
CEL-SCI Corporation, a company duly established pursuant to the laws of Colorado, with the registered office at 8229 Boone Boulevard, Suite 802, Vienna, VA, 22182. USA, hereinafter: “CEL-SCI”)
MASTER SERVICE AGREEMENT between ERGOMED CLINICAL RESEARCH Ltd. Surrey Research Park Guildford GU2 7YD Surrey, England and CEL-SCI Corporation Vienna, VA 22182, USAMaster Service Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances) • England
ERGOMED CLINICAL RESEARCH Ltd., with registered offices at 26-28 Frederick Sanger Road, Surrey Research Park, Guildford, GU2 7YD Surrey, England (hereinafter “ERGOMED”),
AMENDMENT #01_ to Project Agreement No 01, Client Project Number: CSCI-7027Project Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances)
THIS AMENDMENT #01 (“Amendment #01”), dated July 30, 2013 (the “Effective Date”), is by and between CEL-SCI Corporation, with offices at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182 USA (hereinafter referred to as “Client”) and Aptiv Solutions, Inc., together with its Affiliates, with offices at 1925 Isaac Newton Square, Suite 100, Reston, Virginia 20190, USA (hereinafter referred to as “Aptiv Solutions”).
FIRST AMENDMENT TO CO-DEVELOPMENT AGREEMENTCo-Development Agreement Ii • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances)
This First Amendment (“First Amendment”) to the Co-Development Agreement II and Revenue Sharing Agreement (“Co-Development Agreement II”) made on October 24, 2013, between CEL-SCI Corporation, a company duly established pursuant to the laws of Colorado, with the registered office at 8229 Boone Boulevard, Suite 802, Vienna, VA, 22182, USA (hereinafter: “CEL-SCI”) and Ergomed Clinical Research, Ltd., a company duly established pursuant to the laws of England, with registered offices at The Surrey Technological Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG, England (hereinafter: “Ergomed”) is effective as of October 24, 2013.
JOINDER AGREEMENT TO EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT, DATED August 7, 2008Joinder Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances)
